Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), XXXX ( @entity549 ), Medullary Breast Cancer ( @entity0 ) in the Korean Population.

@entity1 @entity0 @entity5 @entity549 @entity1349
BACKGROUND: Despite the favorable prognosis for @entity0 ( @entity0 ), the guidelines for the use of adjuvant chemotherapy for @entity0 have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean @entity1 with node-negative (N0), @entity549 ( @entity549 ) @entity0 @entity1 . METHODS: We included data from 252 @entity1 with N0 @entity549 @entity0 , obtained from the Korean Breast Cancer Registry database. @entity1 were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, @entity0 -specific survival (BCSS), and @entity1349 ( @entity1349 ) were compared between the groups. In addition, a subgroup analysis for survival based on @entity5 size was conducted. RESULTS: A total of 252 N0 @entity549 @entity0 @entity1 with @entity5 sizes >1 cm who were diagnosed between April 1997 and March 2011 were enrolled. The median age was 44.95 years (range, 25-72 years), and the median follow-up period was 93.94 months (range, 23-195 months). Overall, the BCSS and @entity1349 in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in @entity1 with @entity5 >2 cm in size, those in group II had significant better BCSS and @entity1349 (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with @entity5 1-2 cm in size, there were no significant differences in BCSS and @entity1349 between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and @entity1349 (P = 0.007), but only for @entity1 with @entity5 (>2 cm). CONCLUSIONS: In @entity1 with N0 @entity549 @entity0 , adjuvant chemotherapy had a significant clinical survival benefit, but only in those with @entity5 >2 cm.
